莱茵生物增收减利获新主注入6亿资产 秦本军6.5亿脱手控制权质押率超65%

Core Viewpoint - The transfer of control and asset injection into Rhine Biotech is seen as a crucial move to address the company's operational challenges and enhance its market position following the departure of its founder due to regulatory penalties [1][2]. Group 1: Control Change and Asset Injection - Rhine Biotech's controlling shareholder, Qin Benjun, plans to transfer 8.09% of shares to Guangzhou Defu Nutrition for 645.6 million yuan, relinquishing 25.5% of voting rights [1][3]. - After the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as joint actual controllers [1][3]. - The company will also acquire an 80% stake in Beijing Jinkangpu Food Technology through a share issuance, marking a significant asset injection [1][5]. Group 2: Financial Performance and Challenges - For the first three quarters of 2025, Rhine Biotech reported revenues of 1.272 billion yuan, an increase of 8.73%, but a net profit of 70.4 million yuan, down 30.73% year-on-year [1][8]. - Qin Benjun faces significant financial pressure, with over 65% of his shares pledged and a financing balance of 207 million yuan due within six months [1][8]. Group 3: New Business Direction - The acquisition of Beijing Jinkangpu, a leader in food nutrition fortifiers, allows Rhine Biotech to enter the nutrition health sector, expanding its business model [7][10]. - Beijing Jinkangpu's revenue for 2023 to the first nine months of 2025 was 370 million yuan, 432 million yuan, and 338 million yuan, respectively [9]. - The transaction is expected to create a closed-loop industry chain from raw materials to formulation solutions, enhancing operational stability and risk resilience for Rhine Biotech [10]. Group 4: Market Reaction - Following the announcement of the control change and restructuring plan, Rhine Biotech's stock price hit the daily limit, closing at 9.57 yuan per share, a 10% increase [11].